STRONG SALES GROWTH IN THE US
"I am proud of the strategic progress we have achieved during the quarter and the organization's ability to adapt the business to the current circumstances." Emil Billbäck, CEO.
APRIL -
· Net sales decreased by 3 percent and amounted to
· The
· The
· The gross margin was 86.7 percent (86.5). The gross margin was suppressed by fixed production costs in combination with lower net sales.
· Operating result amounted to
· Earnings per share, before and after dilution, were
JANUARY -
· Net sales increased by 14 percent and amounted to
· The
· The
· The gross margin was 87.8 percent (86.2).
· Operating result amounted to
· Earnings per share, before and after dilution, were
SIGNIFICANT EVENTS
· BONESUPPORT announced in April that the Company had submitted a De Novo application to the
· In May, BONESUPPORT carried out a directed new share issue of
·
· In June, BONESUPPORT announced that the Company is starting its own sales organization in
· Patient recruitment to FORTIFY ended in June, following a FDA approval.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se
This information is such information as
About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT (https://www.bonesupport.com/en-eu/cerament%e2%84%a2/). The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (
BONESUPPORT and CERAMENT are registered trademarks (https://www.bonesupport.com/trademarks.html) of
https://news.cision.com/bonesupport-holding-ab/r/bonesupport-holding-ab--publ----publishes-q2-2020-interim-report,c3153041
https://mb.cision.com/Main/16090/3153041/1280363.pdf
(c) 2020 Cision. All rights reserved., source